Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
- PMID: 19914720
- DOI: 10.1016/j.jad.2009.10.023
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
Abstract
Background: Numerous studies have demonstrated an association between bipolar disorder (BD) and obesity. However, these reports are limited by retrospective or cross-sectional designs, and the assessment of patients with lengthy illnesses. Prospective data, and data on weight gain early in the course of BD, are lacking.
Methods: We prospectively measured weight gain and laboratory metabolic indices over 12 months in 47 patients with BD receiving maintenance treatment following their first manic episode, and in 24 age- and gender-matched healthy subjects.
Results: Although approximately two-thirds of patients had experienced previous depressive or hypomanic episodes, there was no difference between patients and healthy subjects in mean body mass index or rates of overweight or obesity at recovery from the first mania. Mean weight gain over 12 months was 4.76kg in patients and 1.50kg in healthy subjects (p=0.047). Combined rates of overweight and obesity at 6 months and 12 months exceeded 50% in patients, and were almost double those of healthy subjects. Logistic regression demonstrated that weight gain in the first 6 months was significantly associated with male gender and prescription of olanzapine or risperidone. Patients who were obese at 6 months and/or 12 months had significantly greater mean serum triglyceride levels and fasting glucose levels than non-obese patients.
Limitations: This was a naturalistic study.
Conclusions: Even in patients with previous depressions and hypomanias, clinically significant weight gain in BD begins following the first manic episode, suggesting that it is primarily related to treatment with mood stabilizers and second-generation antipsychotics. However, the very small number of patients in our sample who were medication-free precludes a meaningful analysis of the degree to which weight gain might be an inherent feature of post-manic BD.
Similar articles
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar Disord. 2010 Mar;12(2):172-84. doi: 10.1111/j.1399-5618.2010.00797.x. Bipolar Disord. 2010. PMID: 20402710
-
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.J Affect Disord. 2008 Jan;105(1-3):45-52. doi: 10.1016/j.jad.2007.04.006. Epub 2007 May 10. J Affect Disord. 2008. PMID: 17498812
-
The antidepressant effects of risperidone and olanzapine in bipolar disorder.Can J Clin Pharmacol. 2004 Fall;11(2):e218-26. Epub 2004 Oct 4. Can J Clin Pharmacol. 2004. PMID: 15520475 Clinical Trial.
-
Atypical antipsychotics: newer options for mania and maintenance therapy.Bipolar Disord. 2005;7 Suppl 4:21-33. doi: 10.1111/j.1399-5618.2005.00212.x. Bipolar Disord. 2005. PMID: 15948764 Review.
Cited by
-
Cannabidiol as a Treatment for Mood Disorders: A Systematic Review.Can J Psychiatry. 2020 Apr;65(4):213-227. doi: 10.1177/0706743719895195. Epub 2019 Dec 13. Can J Psychiatry. 2020. PMID: 31830820 Free PMC article.
-
Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.Pharmacol Res. 2012 Oct;66(4):283-91. doi: 10.1016/j.phrs.2012.06.010. Epub 2012 Jun 29. Pharmacol Res. 2012. PMID: 22750665 Free PMC article.
-
Hippocampus size does not correlate with body mass index in bipolar disorder.Braz J Psychiatry. 2016 Mar;38(1):86-7. doi: 10.1590/1516-4446-2015-1816. Braz J Psychiatry. 2016. PMID: 27111704 Free PMC article. No abstract available.
-
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug Saf. 2012 Oct 1;35(10):819-36. doi: 10.1007/BF03261978. Drug Saf. 2012. PMID: 22967188
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical